Potential Malaria Vaccine Disappoints in New Trial
A recent clinical trial involving African infants ages 6–12 weeks revealed that a potential malaria vaccine was only 30% effective in reducing episodes of the disease, Reuters reports. The mosquito-borne illness infected about 216 million people worldwide in 2010. Other control measures such as insecticide-treated bug netting have decreased malaria-related deaths in recent years, and scientists hoped that the vaccine, known as RTS,S or Mosquirix, would continue to cut infection and mortality rates. Philanthropist and Microsoft co-founder Bill Gates helped fund the development, and calls for further research. If effective, the vaccine would likely be added to routine infant immunizations in the most-impacted countries.
Image: Newborn via Shutterstock.